uniQure N.V. (QURE)
- Previous Close
14.26 - Open
14.24 - Bid 10.31 x 200
- Ask 18.03 x 200
- Day's Range
13.90 - 14.50 - 52 Week Range
3.73 - 19.18 - Volume
618,870 - Avg. Volume
1,393,249 - Market Cap (intraday)
771.137M - Beta (5Y Monthly) 0.42
- PE Ratio (TTM)
-- - EPS (TTM)
-4.92 - Earnings Date Feb 27, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
36.11
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
www.uniqure.comRecent News: QURE
View More
Performance Overview: QURE
Trailing total returns as of 4/25/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: QURE
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: QURE
View MoreValuation Measures
Market Cap
766.81M
Enterprise Value
465.35M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
25.44
Price/Book (mrq)
--
Enterprise Value/Revenue
17.16
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-16.39%
Return on Equity (ttm)
-238.46%
Revenue (ttm)
27.12M
Net Income Avi to Common (ttm)
-239.56M
Diluted EPS (ttm)
-4.92
Balance Sheet and Cash Flow
Total Cash (mrq)
367.52M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-139.79M
Research Analysis: QURE
View MoreResearch Reports: QURE
View MoreLowering target price to $8.00
UNIQURE NV has an Investment Rating of HOLD; a target price of $8.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Low; and a Value Subrating of Low.
RatingPrice TargetWhat does Argus have to say about QURE?
UNIQURE NV has an Investment Rating of HOLD; a target price of $9.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Low; and a Value Subrating of High.
RatingPrice TargetWhat does Argus have to say about QURE?
UNIQURE NV has an Investment Rating of HOLD; a target price of $9.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Low; and a Value Subrating of High.
RatingPrice TargetLowering target price to $9.00
UNIQURE NV has an Investment Rating of HOLD; a target price of $9.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
RatingPrice Target